.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Chubb
Queensland Health
UBS
QuintilesIMS
Novartis
Boehringer Ingelheim
Covington
Merck
Baxter

Generated: November 24, 2017

DrugPatentWatch Database Preview

AUGMENTIN XR Drug Profile

« Back to Dashboard

What is the patent landscape for Augmentin Xr, and when can generic versions of Augmentin Xr launch?

Augmentin Xr is a drug marketed by Dr Reddys Labs Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-six patent family members in forty-eight countries.

The generic ingredient in AUGMENTIN XR is amoxicillin; clavulanate potassium. There are forty-four drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the amoxicillin; clavulanate potassium profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Dr Reddys Labs Inc
AUGMENTIN XR
amoxicillin; clavulanate potassium
TABLET, EXTENDED RELEASE;ORAL050785-001Sep 25, 2002ABRXYesYes► Subscribe► Subscribe ► Subscribe
Dr Reddys Labs Inc
AUGMENTIN XR
amoxicillin; clavulanate potassium
TABLET, EXTENDED RELEASE;ORAL050785-001Sep 25, 2002ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Dr Reddys Labs Inc
AUGMENTIN XR
amoxicillin; clavulanate potassium
TABLET, EXTENDED RELEASE;ORAL050785-001Sep 25, 2002ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Dr Reddys Labs Inc
AUGMENTIN XR
amoxicillin; clavulanate potassium
TABLET, EXTENDED RELEASE;ORAL050785-001Sep 25, 2002ABRXYesYes► Subscribe► Subscribe ► Subscribe
Dr Reddys Labs Inc
AUGMENTIN XR
amoxicillin; clavulanate potassium
TABLET, EXTENDED RELEASE;ORAL050785-001Sep 25, 2002ABRXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for AUGMENTIN XR

Drugname Dosage Strength RLD Submissiondate
amoxicillin and clavulanate potassiumExtended-release Tablets1000 mg/62.5 mgAugmentin XR1/21/2009

Non-Orange Book Patents for Tradename: AUGMENTIN XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,294,199 Method of treating a bacterial infection comprising administering amoxycillin► Subscribe
6,660,299 Modified release pharmaceutical formulation comprising amoxycillin► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: AUGMENTIN XR

Country Document Number Estimated Expiration
TaiwanI235067► Subscribe
United Kingdom0008923► Subscribe
Czech Republic20001311► Subscribe
Netherlands1014914► Subscribe
Germany20006626► Subscribe
Eurasian Patent Organization004310► Subscribe
United Kingdom0122638► Subscribe
Uruguay26104► Subscribe
Netherlands1014915► Subscribe
European Patent Office1269997► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Accenture
Fuji
McKinsey
Express Scripts
Cantor Fitzgerald
US Department of Justice
Baxter
UBS
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot